Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 15

The DOI matches its Crossref record.

Functional gastrointestinal disorders in children: Effectivity, safety, and tolerability of the herbal preparation STW-5 (Iberogast®) in general practice

Michael, Radke, Bettina, Vinson, Eckehard, Lehmann·2022·Complementary Therapies in Medicine
DOI 10.1016/j.ctim.2022.102873
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ctim.2022.102873

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 26

  1. Saps, 2018, Prevalence of functional gastrointestinal disorders in children and adolescents: comparison between Rome III and Rome IV criteria, J Pediatr, 199, 212, 10.1016/j.jpeds.2018.03.037 · DOI
  2. Park, 2015, Inpatient burden of childhood functional GI disorders in the USA: an analysis of national trends in the USA from 1997 to 2009, Neurogastroenterol Motil, 27, 684, 10.1111/nmo.12542 · DOI
  3. Mahon, 2017, The costs of functional gastrointestinal disorders and related signs and symptoms in infants: a systematic literature review and cost calculation for England, BMJ Open, 7, 10.1136/bmjopen-2016-015594 · DOI
  4. Liebman, 1978, Recurrent abdominal pain in children: a retrospective survey of 119 patients, Clin Pediatr, 17, 149, 10.1177/000992287801700208 · DOI
  5. Ammoury, 2009, Functional gastrointestinal disorders: past and present, World J Pediatr, 5, 103, 10.1007/s12519-009-0021-6 · DOI
  6. Drossman, 2006, The functional gastrointestinal disorders and the Rome III process, Gastroenterology, 130, 1377, 10.1053/j.gastro.2006.03.008 · DOI · Paper page
  7. Chogle, 2009, Environmental factors of abdominal pain, Pediatr Ann, 38, 398, 10.3928/00904481-20090622-10 · DOI
  8. Rasquin, 2006, Childhood functional gastrointestinal disorders: child/adolescent, Gastroenterology, 130, 1527, 10.1053/j.gastro.2005.08.063 · DOI
  9. Madisch, 2001, Ein Phytotherapeutikum und seine modifizierte Rezeptur bei funktioneller Dyspepsie, Z Gastroenterol, 39, 1, 10.1055/s-2001-16142 · DOI
  10. Melzer, 2004, Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast), Aliment Pharm Ther, 20, 1279, 10.1111/j.1365-2036.2004.02275.x · DOI
  11. Malfertheiner, 2017, STW 5 (Iberogast) therapy in gastrointestinal functional disorders, Dig Dis, 35, S25, 10.1159/000485410 · DOI · Paper page
  12. von Arnim, 2007, STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicentre, placebo-controlled double-blind study, Am J Gastroenterol, 102, 1268, 10.1111/j.1572-0241.2006.01183.x · DOI
  13. Buchert, 1994, Wirksamkeit und Verträglichkeit von Iberogast bei Patienten mit gesicherter Non Ulcus Dyspepsie, Z Phytother, 15, 45
  14. Rösch, 2002, A randomised clinical trial comparing the efficacy of herbal preparation STW-5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia, Z Gastroenterol, 40, 401, 10.1055/s-2002-32130 · DOI
  15. Madisch, 2004, Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomised, placebo-controlled, multi-centre trial, Aliment Pharm Ther, 19, 271, 10.1111/j.1365-2036.2004.01859.x · DOI · Paper page
  16. Sassin, 2000, Efficacy and tolerability of the herbal preparation Iberogast® in the therapy of functional dyspepsia, Phytomedicine, 7, S91
  17. Klein-Galczinsky, 1999, Anwendungsbeobachtung zur Wirksamkeit und Verträglichkeit von Iberogast® in der Therapie des Colon irritabile, Phytother der Schwelle zum neuen Jahr (Abstr), 125, P25
  18. Abdel-Aziz, 2017, Evaluating the multitarget effects of combinations through multistep clustering of pharmacological data: the example of the commercial preparation Iberogast, Planta Med, 2017, 1130
  19. Allescher, 2007, STW 5/Iberogast: multi-Target-Wirkung bei funktioneller Dyspepsie und Reizdarmsyndrom, Wien Med Woche, 157, 301, 10.1007/s10354-007-0429-3 · DOI
  20. Adam, 2005, Validation of the gastrointestinal symptom score for the assessment of symptoms in patients with functional dyspepsia, Aliment Pharm Ther, 22, 357, 10.1111/j.1365-2036.2005.02572.x · DOI
  21. Holtmann, 2004, Clinical presentation and personality factors are predictors of the response to treatment in patients with functional dyspepsia: a randomised, double-blind placebo-controlled crossover study, Dig Dis Sci, 49, 672, 10.1023/B:DDAS.0000026317.00071.75 · DOI
  22. Raedsch, 2018, Early onset of efficacy in patients with functional and motility-related gastrointestinal disorders: a non-interventional study with Iberogast®, Wien Med Woche, 168, 89, 10.1007/s10354-017-0578-y · DOI
  23. Schemann, 2006, Region-specific effects of STW 5 (Iberogast) and its components in gastric fundus, corpus, and antrum, Phytomedicine, 13, S90, 10.1016/j.phymed.2006.03.020 · DOI
  24. Pilichiewicz, 2007, Effects of Iberogast on proximal gastric volume, antropyloroduodenal motility, and gastric emptying in healthy men, Am J Gastroenterol, 102, 1276, 10.1111/j.1572-0241.2007.01142.x · DOI
  25. Schemann M. Iberogast® – Focus regionenspezifische Motilität. Iberogast® Symposium. Bad Wörishofen, Germany; 2010.
  26. Krueger, 2009, The multi-herbal drug STW 5 (Iberogast) has prosecretory action in the human intestine, Neurogastroenterol Motil, 21, 1203, 10.1111/j.1365-2982.2008.01242.x · DOI

Cited by

Metadata

Authors
Michael, R., Bettina, V., & Eckehard, L.
Venue
Complementary Therapies in Medicine
Publisher
Elsevier BV
Published
2022-12
Volume
71
Pages
102873
ISSN
0965-2299
DOI
10.1016/j.ctim.2022.102873
Cited by
15
References
0
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.